CDH is associated with lung hypoplasia, pulmonary hypertension, and left ventricular hypoplasia. Use of new STE techniques (heart ultrasound) showed that CDH newborns have decreased LV size and function, potentially explaining the non-response to iNO, and that these cardiac findings were associated with poor outcomes. Our hypothesis: CDH newborns persist to have some degree of LV hypoplasia in the pediatric and adolescent life and pulmonary pressures remain increased during growth. Patients with decreased cardiac performance by STE and/or with PH have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of cardiac function
Timeframe: Within 24 hours of life
Assessment of cardiac function
Timeframe: Between day 3 to 5 of life
Assessment of cardiac function
Timeframe: Between 2 to 3 weeks of life
Assessment of cardiac function
Timeframe: age of 4 and/or 9 months
Assessment of cardiac function
Timeframe: 3, 5 and/or 8 years
Assessment of cardiac function
Timeframe: 11, 14 and/or 17 years